Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

MK-8591 shows promise as a novel HIV prophylaxis drug in preclinical and early clinical setting

July 27, 2017

Phase III data for glecaprevir/pibrentasvir combination in HIV-1/HCV coinfected patients presented

July 26, 2017

Frontier Biotechnologies enters agreement with Rockefeller University

July 26, 2017

ALT-803 induces NK- and T-cell activation in SIV-infected macaques

July 26, 2017

EMA committee backs approval of Janssen's Symtuza

July 24, 2017

Merck & Co. divulges HIV integrase inhibitors

July 17, 2017

Gilead Sciences' MAA for bictegravir/emtricitabine/tenofovir alafenamide FDC validated by EMA

July 14, 2017

FDA gives ibalizumab BLA priority review

July 3, 2017

ViiV Healthcare presents novel anti-HIV compounds

June 20, 2017

Gilead Sciences submits NDA in U.S. for bictegravir/emtricitabine/tenofovir alafenamide

June 13, 2017

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...